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NUT Midline Carcinoma Masquerading As a
Thymic Carcinoma
Introduction
Thymic carcinomas are rare tumors that arise from the epithe-
lium of the thymus gland and characterized by cytologic atypia, inva-
siveness, and high risk of relapse and death.1-3 The current WHO
schema recognizes at least 11 histologic subtypes.4-7 Undifferentiated
thymic carcinoma is one of the subtypes that can be indistinguishable
from other poorly differentiated carcinomas such as NUT midline
carcinoma (NMC).8 Despite the aggressive nature of both diseases, a
correct diagnosis is important because of the recent development of
targeted therapies for NMCs. Herein we describe two cases of a par-
ticularly aggressive formof disease anddiscuss the differential diagno-
sis of these lesions.
Case Report 1
The ﬁrst patient was a 22-year-old African American/Asian
college-age woman whose pertinent history began approximately 3
months before she presented to the hospital. At that time, the patient
began to experiencemild exertional dyspnea.Because shehad recently
moved fromIndiana toFlorida, she atﬁrst attributed the symptoms to
her alteredwork environment. The patient eventually soughtmedical
attention and was prescribed inhalers for suspected reactive airway
disease; the symptoms worsened. Chest x-ray showed mediastinal
widening and chest computed tomography (CT) imaging revealed a
large mediastinal mass. The patient came to Indiana University for
further work-up and evaluation.
At admission, the patient reported shortness of breath withmild
exertion, nonproductive cough for several weeks, and a 5-lb weight
loss. Thepatient denied fever or chills andhadnoheadaches, syncope,
dizziness, bone pain, nausea, or vomiting. The clinical examination
was unremarkable except for decreased breath sounds and slight dull-
ness to percussion on the left. Her routine laboratory work-up was
unremarkable. A chest CT scan showed a mediastinal mass that had
signiﬁcantly increased in 1month (Fig 1). There was bulky conﬂuent
pretracheal andsubcarinal lymphadenopathywithcompressionof the
distal carinaand leftmain stembronchus.Anopenmediastinal biopsy
was performed after the failure of a CT-guided biopsy. This showed a
poorly differentiated carcinoma most likely consistent with thymic
carcinoma (histologic features to be described). Flow cytometry from
tissue obtained revealed T cells and polyclonal B cells and no immu-
nophenotypic evidence of malignancy. A staging CT scan showed no
evidence ofmetastatic disease. The patient obtained a partial response
after six cycles of carboplatin and paclitaxel. Neither surgery nor
radiationwas performedbecause of the size and location of the lesion.
Six months after the completion of chemotherapy, the patient
presented with marked dyspnea at rest. Chest x-ray and CT scan
conﬁrmed tumor recurrence. Salvage chemotherapy with cisplatin,
doxorubicin, and cyclophosphamide was begun, and the patient re-
sponded well. Left pneumonectomy with mediastinal lymphadenec-
tomy was performed. During the recovery period, the patient
developedneurologic symptomsandwas found tohave cystic cerebel-
lar metastases on CT (Fig 2A) andmagnetic resonance imaging scans
(Fig 2B). She underwent resection of this lesion and received radio-
therapy toherchest andherhead.Thepatientdidwell for aboutayear,
but then she was admitted to a local hospital for syncope and cardiac
arrest and died soon afterward.
Case Report 2
The second patient, a 37-year-old white woman, was experienc-
ing bronchitis and back pain; the latter she attributed to the care of an
11-year-old child with severe cerebral palsy. She had recently been
diagnosed with pneumonia and had signiﬁcant pleuritic pain in the
right upper back and paravertebral region. Routine chest x-ray
showed right middle lobe atelectasis and a 4.6-cm right paratra-
cheal mass. Additionally, extensive mediastinal and right hilar
lymphadenopathy was seen on chest CT (Fig 3). A needle biopsy
suggested the diagnosis of thymoma. However, clinical suspicion
of lymphoma led to mediastinoscopic biopsy. Flow cytometry of
the biopsy sample was limited by low cellularity but showed poly-
clonal B cells and mature T cells. Following a surgical pathology
consultation, a deﬁnitive diagnosis of thymic carcinoma was made
(histologic features to be described).
The patient came to IndianaUniversity for furthermanagement
of thymic carcinoma. Evaluation of her CT scan showed extensive
middle mediastinal disease as well as an anterior mediastinal mass.
The patient was found to have baseline thrombocytopenia and was
treated with carboplatin and paclitaxel. She received four cycles of
Fig 1.
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carboplatin plus paclitaxel for thymic carcinoma but had to discon-
tinue therapy because of persistent and nonresolving pancytopenia
that was believed to be of autoimmune etiology. She developed pares-
thesias of her left jaw, which were conﬁrmed to be metastases by
ﬁne-needle aspiration biopsy.Metastases to pleura, left shoulder, hip,
and vertebral column (Fig 4) were also detected. Brain magnetic res-
onance imaging with and without contrast showed diffuse cerebral
meningeal metastases as well as diffuse bone metastases. She under-
went palliative radiation therapy and was discharged to hospice 6
months after diagnosis, where she died shortly afterward.
Histologic features. The histologic features of both patients were
similar. The tumors were composed of mixed undifferentiated small
cells with foci of squamous differentiation (Fig 5). The small-cell
components lacked the features that are typically associated with
small-cell carcinoma of the lung; that is, no nuclearmolding and high
mitotic and apoptotic activity. Abrupt foci of squamous differentia-
tion characterized by small islands of cells with keratinized, pink
cytoplasm were scattered within the tumors. The squamous cells had
bland, nuclear features and did not show mitotic activity. The tumor
cells demonstrated immunoreactivity for CD5 and cytokeratin cock-
tail, whereas synaptophysin, CK20, and CK7 were negative. Areas of
squamous differentiation were highlighted by an antibody against
high–molecular-weight cytokeratin (34E12). The tumor cells ex-
pressed NUT protein, conﬁrming the diagnosis of NMC (Fig 6).
Discussion
NMC, also called carcinoma with t(15;19) translocation, is a
variant of poorly differentiated squamous cell carcinoma that is char-
acterizedby chromosomal rearrangementof theNUTgene locatedon
chromosome15.9Theclassic chromosomal rearrangement consistsof
translocatedNUTgene in-framewithBRD4, aubiquitously expressed
transcriptional coactivator. This translocation is not present in some
cases of NMC, which are referred to as NUT variants. Instead, a
pairing of NUTwith BRD3 is noted.10 In a small number of cases, the
molecular basis is not yet understood. Although NMCs have been
BA
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classically described in children and adolescents, they have also been
reported in adults.9,11NMCis apoorly recognized entity bothbecause
of the location of the tumors and the histologic features.9 The tumors
are often located in themidline and confused with sinonasal carcino-
mas and lung carcinomas.Histologically, the tumors are composed
of a variable mix of primitive, undifferentiated cells and squamous
cells. The predominance of the former leads to the misdiagnosis of
small blue cell tumors (Ewing sarcoma, neuroblastoma, small-cell
carcinoma), whereas the latter leads to the misdiagnosis of poorly
differentiated carcinoma or squamous cell carcinoma. The recent
development of an immunohistochemistry assay for NUT protein
has led to increased recognition of NMCs in adults.10
In both of the patients we describe, the tumors were predomi-
nantly composedof primitive, undifferentiated cellswithinwhich foci
of abrupt squamous differentiation were identiﬁed. Neither undiffer-
entiated complements resembled classical small-cell carcinoma. In
addition, neuroendocrine markers, which are typically positive in
small-cell carcinoma, were not expressed by the tumor cells. The
expression of NUT protein enabled a deﬁnitive diagnosis to be made
in both of these patients.
The clinical course in both patients was aggressive, leading to
deathwithin 18months of initial diagnosis. This is consistentwith the
clinical behavior described in the literature for NMCs. In the series by
Bauer et al,9 the progression-free survival (PFS) of 25 adult patients
was 4% at 1 and 2 years. The overall survival (OS)was 16% and 5%at
1 and 2 years, respectively. In this large series, there was no status
difference in PFS or OS by patient age, sex, tumor histology, lymph
node involvement, or the exact type of translocation.
Oneof thepatientspresentedherehad thrombocytopenia,which
was thought to be of autoimmune origin. This is unusual for patients
with thymic carcinoma;myasthenia and autoimmune syndromes are
more typical in thymomas.
The optimal treatment for patients with NMC is unclear. Al-
though a number of therapeutic regimens have been used, the overall
effectiveness of chemotherapy is questionable. In the series byBauer et
al,9 gross total resection was associated with improved survival (both
PFS andOS). Intriguingly, these tumors seem to respondwell to early
administration of radiotherapy. Recent laboratory studies have sug-
gested that the NUT fusion protein results in aberrant histone acety-
lation and blockade of differentiation. Efforts have been made to
develop targeted therapeutic approaches such as direct acting
inhibitors of BRD3 and BRD4 bromodomain (BETi) and histone
deacetylase inhibitors (HDACi).12,13 A phase I clinical trial of BETi
(GlaxoSmithKline, Philadelphia, PA) is available to patients with
NMC. Additionally, HDACi demonstrated promising clinical re-
sponse in pediatric patients.14
In summary, NMC is an increasingly recognized lesion that can
be diagnosed by immunohistochemistry for NUT protein. This in
turn will lead to recognition of adult cases and a full spectrum of
clinical andpathologic features. The tumors tend tobe aggressive, and
it seems that surgery and radiation-based regimensmight be optimal.
Novel therapies such asHDACi andBETi are being developed to treat
this rare form of cancer. These recent developments emphasize the
importanceof includingNMCin thedifferentialdiagnosis forpatients
with poorly differentiated carcinomas that arise in close proximity to
the midline.
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